arrow
D

Dachuan Huang

lymphoma translational research laboratory
H指数:27
被引数:5,502

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma

Brincidofovir在周围T细胞和NK/T细胞淋巴瘤中的临床前活性

2026-02-060
OAAI
Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma- Potential Synergy with Immune Checkpoint Blockade

非霍奇金淋巴瘤中布马那韦的治疗重定位——与免疫检查点阻断的潜在协同作用

BLOOD
IF23.1
2024-11-050
PRE
CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma

CDK4/6抑制增强XPO1抑制剂selinexor在自然杀伤/T细胞淋巴瘤中的抗肿瘤功效

2024-08-010
OA
Potent anti-proliferative activity of brincidofovir in Diffuse Large B-cell Lymphoma with overexpression of transcriptional repressor TLE1
2024-03-220
PRE
Single-Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T-Cell Lymphoma

单细胞分析揭示恶性细胞重塑细胞景观并促进结外NK/T细胞淋巴瘤的免疫抑制微环境

2023-11-104
OA
PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma

PBRM1-deficient PBAF复合物靶向异常基因组位点以激活透明细胞肾细胞癌中的nf-κb途径

2023-04-247
PRE
Single cell landscape of multicentric Castleman disease in identical twins
2023-04-040
PRE
Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide
2023-02-0610
OAAI
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma
2022-10-1916
PRE
A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort
2022-07-056
OAAI
CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma
2021-11-0113
OAAI
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
2021-10-169
OAAI
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (vol 34, 3413, 2020)
LEUKEMIA
IF13.4
2021-03-080
OAAI
No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma
2020-10-131
OAAI
Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma
2020-10-0564
OA
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
LEUKEMIA
IF13.4
2020-08-0560
OAAI